Q32 Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-83.09	-112.96	-5.01	-95.76	-128.69	-103.92	Upgrade
Depreciation & Amortization	2.32	2.64	2.6	9.54	8.9	6.32	Upgrade
Share-Based Compensation	5.37	7.32	13.05	17.25	13.25	7.64	Upgrade
Other Operating Activities	-9.33	6.76	-124.31	-40.78	12.21	-1.4	Upgrade
Operating Cash Flow	-84.73	-96.23	-113.66	-109.75	-94.33	-91.36	Upgrade
Capital Expenditures	0.55	0.33	-1.29	-2.4	-3.73	-21.83	Upgrade
Acquisitions	0	0	130	0	0	0	Upgrade
Change in Investments	69.5	101	-92	-48.39	208.63	-29.97	Upgrade
Investing Cash Flow	70.05	101.33	36.72	-50.79	204.9	-51.8	Upgrade
Share Issuance / Repurchase	95.19	0.18	0.6	52.17	53.09	158.21	Upgrade
Debt Issued / Paid	7	0	0	0	0	0	Upgrade
Other Financing Activities	-2.81	-	-	-	-	-	Upgrade
Financing Cash Flow	99.38	0.18	0.6	52.17	53.09	158.21	Upgrade
Net Cash Flow	84.7	5.28	-76.35	-108.37	163.66	15.06	Upgrade
Free Cash Flow	-84.17	-95.9	-114.95	-112.15	-98.07	-113.19	Upgrade
Free Cash Flow Margin	-23777.68%	-8296.19%	-3583.10%	-330.13%	-3629.35%	-6794.18%	Upgrade
Free Cash Flow Per Share	-84.57	-29.85	-36.05	-36.52	-38.45	-48.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).